Annals of Cancer Research and Therapy
Online ISSN : 1880-5469
Print ISSN : 1344-6835
ISSN-L : 1344-6835
Role of IL-18 on the activation of Vδ2+ T cells – For the development of novel cancer immunotherapy –
Yuki AbeHirohito KobayashiYoshika AkizawaKen IshitaniHideo Matsui
著者情報
ジャーナル フリー

2018 年 26 巻 2 号 p. 71-76

詳細
抄録

IL(interleukin)-18 is known to induce proliferation of Vδ2+ T cells and expression of CD56, resulting in enhancement of cytotoxic activity. We focused on the expression of CD56 and the direct action of IL-18 on Vδ2+ T cells to evaluate the importance of IL-18 for developing Vδ2+ T cells-based adoptive immunotherapy. Peripheral blood mononuclear cells (PBMCs) were purified from heparinized blood of healthy donors and cancer patients. CD562+ T cells isolated from healthy subjects were cultured with IL-2 and IL-18 or with IL-2 alone. The number of CD562+ cells increased compared with those with IL-2 alone. However, this increase was not statistically significant. CD562+ T cells derived from CD56+-depleted PBMCs were stimulated by phosphoantigens and cultured with IL-2 and IL-18, and showed significantly stronger cytotoxic activity than resultant CD56+2+ T cells. IL-18 promotes the proliferation of Vδ2+ T cells from PBMCs of ovarian cancer patients. Thus, IL-18 is worth to be considered as a strong candidate in the development of effective cancer immunotherapy.

著者関連情報
© 2018 by The Japanese Society of Strategies for Cancer Research and Therapy
次の記事
feedback
Top